US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

157.47

+1.230.79%

Post-market: 156.75-0.7190-0.46%19:59 EDT

Volume:420.43K

Turnover:66.72M

Market Cap:531.38M

PE:- -

High:161.26

Open:157.46

Low:155.50

Close:156.24

52wk High:198.18

52wk Low:32.55

Shares:3.37M

Float Shares:3.22M

Volume Ratio:0.60

T/O Rate:13.04%

Dividend:1.34

Dividend Rate:0.85%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears

Simply Wall St.

Sector Update: Health Care

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Stevanato Group (STVN) and BioNTech SE (BNTX)

Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Tonix Pharma (TNXP)

Elizabeth Warren Says 'Hard No' To Trump's $50 Billion Iran War Funding Request: Congress 'Could Afford' Health Care Tax Credits Instead

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

Yestar Healthcare Sets March 2026 Board Meeting to Review 2025 Results and Dividend

Government Work Report Highlights Commercial Health Insurance for the First Time: Where is the Trillion-Yuan Market Headed?

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV)

Hunan Warrant Pharmaceutical Subsidiary Passes US FDA Inspection for Peptic Ulcer Drug Raw Ingredient

MT Newswires Live

J.P. Morgan Remains a Buy on Merck KGaA (0O14)

BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100

China's Basic Medical Insurance Coverage Exceeds 1.33 Billion in 2025

Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating

COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":157.47,"timestamp":1773777600000,"preClose":156.24,"halted":0,"volume":420430,"hourTrading":{"tag":"盘后","latestPrice":156.751,"preClose":157.47,"latestTime":"19:59 EDT","volume":3057,"amount":479906.9481,"timestamp":1773791971988,"change":-0.719,"changeRate":-0.004566,"amplitude":0.005461},"delay":0,"changeRate":0.00787250384024571,"floatShares":3224486,"shares":3374486,"eps":0,"marketStatus":"Not Yet Opened","change":1.23,"latestTime":"03-17 16:00:00 EDT","open":157.46,"high":161.26,"low":155.5,"amount":66715715.926400006,"amplitude":0.036866,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773820800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":156.24,"sharesOutstanding":3074486,"nav":156.375,"aum":527686772.09,"dividendRate":0.0085,"bidAskSpread":0.001729,"preHourTrading":{"tag":"盘前","latestPrice":157.98,"preClose":156.24,"latestTime":"09:28 EDT","volume":3731,"amount":579161.18988,"timestamp":1773754129536,"change":1.74,"changeRate":0.011137,"amplitude":0.022721},"postHourTrading":{"tag":"盘后","latestPrice":156.751,"preClose":157.47,"latestTime":"19:59 EDT","volume":3057,"amount":479906.9481,"timestamp":1773791971988,"change":-0.719,"changeRate":-0.004566,"amplitude":0.005461},"volumeRatio":0.602046,"impliedVol":1.0319,"impliedVolPercentile":0.86},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.602046,"shares":3374486,"dividePrice":1.3385,"high":161.26,"amplitude":0.036866,"preClose":156.24,"low":155.5,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":157.47,"eps":0,"divideRate":0.0085,"volume":420430,"delay":0,"ttmEps":0,"open":157.46,"prevYearClose":159.39,"prevWeekClose":148.85,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":171.5,"twentyDayClose":162.07,"sixtyDayClose":156.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619961469","title":"Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619961469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619961469?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:50","pubTimestamp":1773669007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BK4585","BK4611","LABU","BK4581","BK4588","LU0128526141.USD","BEAM","LU1861558580.USD","PTHS","LU1861559042.SGD","BK4137","BK4505","BK4535","BK4139","XBI","BK4112","BK4556","LU0029874061.USD","BLSX"],"gpt_icon":0},{"id":"2619469692","title":"Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2619469692","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619469692?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:42","pubTimestamp":1773668520,"startTime":"0","endTime":"0","summary":"On Friday, the U.S. Food and Drug Administration  approved Novartis AG’s  Cosentyx for younger patients.The approval covers pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa .HS is a chronic, systemic inflammatory skin disease that causes recurring boil-like lesions, which can rupture into painful wounds and lead to scarring.HS affects as many as1 in 100 people worldwide and often begins around puberty.\"With more than a decade of real-world experience across multiple autoimmune diseases, Cosentyx is a well-established treatment option that many physicians trust,\" said Victor Bultó, President, Novartis US.The studies and pharmacokinetic modeling support the use of Cosentyx in patients aged 12+ with moderate to severe HS weighing 30 kg or more. Researchers extrapolated this modeling from adult HS and psoriasis clinical trials, as well as pediatric clinical trial data from other approved indications.Dosing analysis also supports the approval and predic","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Atopic-Dermatitis-Photo-via-Shutterstock.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Atopic-Dermatitis-Photo-via-Shutterstock.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/03/51269251/novartis-advances-dermatology-portfolio-with-cosentyx-fda-approval-for-pediatric-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51269251/novartis-advances-dermatology-portfolio-with-cosentyx-fda-approval-for-pediatric-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4578","NVS","IE00BFTCPJ56.SGD","BK4007","IE0002141913.USD","BK4585","LU0320765489.SGD","BK4532","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","LABU","LU0070302665.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD"],"gpt_icon":0},{"id":"2619464244","title":"Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464244","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464244?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:10","pubTimestamp":1773666627,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.\nSee our latest analysis for Vera Therapeutics.\nAt a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4539","VERA","LU2324357040.USD","DCF","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2619446552","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2619446552","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619446552?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:02","pubTimestamp":1773666136,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 0.5%.CytomX Therapeutics  shares were up more than 50% after the company said a phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","IBB","XBI","XLV","BK4581","CTMX","BK4139","LABU"],"gpt_icon":0},{"id":"2619071468","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Stevanato Group (STVN) and BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619071468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619071468?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:40","pubTimestamp":1773664806,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ascendis Pharma (ASND – Research Report), Stevanato Group (STVN –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-stevanato-group-stvn-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-stevanato-group-stvn-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","ASND","BK4137","BK4535","LABU","XBI","BK4581","BK4588","BK4548","BK4121","BK4568","STVN","LU0029874061.USD","BNTX","BK4539","XLV","LU0128526141.USD","BK4551","HCSG","BK4585","BK4139"],"gpt_icon":0},{"id":"2619645000","title":"Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645000","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619645000?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:01","pubTimestamp":1773662460,"startTime":"0","endTime":"0","summary":"NEW YORK, March 16, 2026  -- LifeMD, Inc. , a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition.\"I have spent my career partnering with management teams, boards, and investors to build the financial infrastructure that enables high-growth companies to scale efficiently and create lasting value,\" said Mr. Kavthekar. \"LifeMD is at an inflection point, with a vertically integrated platform, expanding insurance capabilities, and a commitment to AI-driven innovation that can meaningfully improve patient outcomes while driving operating lever","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LU0128526141.USD","XBI","BK4022","BK4581","LABU","R","BK4167","BK4137","BK4183","BK4120","TISI","HCSG","BK4232","XLV","BK4585","BK4588","LFMD"],"gpt_icon":0},{"id":"2619946344","title":"Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619946344","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619946344?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"NDA based on positive clinical results from the SUMMIT pivotal trial in which bezuclastinib demonstrated clear clinical benefit across all symptom domainsWALTHAM, Mass. and BOULDER, Colo., March  16, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256200/0/en/Cogent-Biosciences-Announces-FDA-Acceptance-of-New-Drug-Application-for-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","LU1670628061.USD","BK4532","BK4585","BK4588","LU1670627923.USD","CCOI","BK4089"],"gpt_icon":0},{"id":"2619595450","title":"Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Tonix Pharma (TNXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619595450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619595450?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660640,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Tonix ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jade-biosciences-jbio-and-tonix-pharma-tnxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jade-biosciences-jbio-and-tonix-pharma-tnxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4583","BK4585","LU0029874061.USD","TNXP","BK4588","XLV","LABU","BK4539","BK4137","JBIO","HCSG","XBI","BK4581","BK4139"],"gpt_icon":0},{"id":"2619576634","title":"Elizabeth Warren Says 'Hard No' To Trump's $50 Billion Iran War Funding Request: Congress 'Could Afford' Health Care Tax Credits Instead","url":"https://stock-news.laohu8.com/highlight/detail?id=2619576634","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619576634?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:13","pubTimestamp":1773659580,"startTime":"0","endTime":"0","summary":"Senator Warren vows a \"hard NO\" on Trump's $50B Iran war request, arguing the funds should instead cover ACA healthcare tax credits.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Arlington--Va---February-13--2020-Senato.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Arlington--Va---February-13--2020-Senato.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/politics/26/03/51264668/elizabeth-warren-says-hard-no-to-trumps-50-billion-iran-war-funding-request-congress-could-afford-health-care-tax-credits-instead","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/politics/26/03/51264668/elizabeth-warren-says-hard-no-to-trumps-50-billion-iran-war-funding-request-congress-could-afford-health-care-tax-credits-instead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["ACA","XLV","BK4585","XBI","IE00B19Z6F94.USD","BK4588","BK4129","BK4581","LABU","IE0034390439.USD","LU0274383776.USD"],"gpt_icon":0},{"id":"2619450780","title":"NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450780?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256129/0/en/NovaBridge-Announces-Productive-FDA-Type-B-Meeting-on-Potential-Accelerated-Approval-Pathway-for-Givastomig-in-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4585","ORR"],"gpt_icon":0},{"id":"2619591794","title":"Yestar Healthcare Sets March 2026 Board Meeting to Review 2025 Results and Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619591794","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619591794?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:45","pubTimestamp":1773654325,"startTime":"0","endTime":"0","summary":"Yestar Healthcare Holdings Co Ltd ( ($HK:2393) ) has issued an announcement. Yestar Healthcare Holdings has scheduled a board meeting for 27 March ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/yestar-healthcare-sets-march-2026-board-meeting-to-review-2025-results-and-dividend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/yestar-healthcare-sets-march-2026-board-meeting-to-review-2025-results-and-dividend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0128526141.USD","XBI","LU0029874061.USD","BK4588","XLV","LABU","BK4585","HCSG","BK4137"],"gpt_icon":0},{"id":"1160919507","title":"Government Work Report Highlights Commercial Health Insurance for the First Time: Where is the Trillion-Yuan Market Headed?","url":"https://stock-news.laohu8.com/highlight/detail?id=1160919507","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160919507?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:06","pubTimestamp":1773648413,"startTime":"0","endTime":"0","summary":"This year's Government Work Report proposed to \"accelerate the development of commercial health insurance, promote the high-quality development of innovative drugs and medical devices, and better...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","XBI","XLV","BK4581","LABU"],"gpt_icon":0},{"id":"2619458758","title":"AstraZeneca (AZN) Gets a Buy from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619458758?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:05","pubTimestamp":1773648346,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst Luisa Hector maintained a Buy rating on AstraZeneca today and set a price target of £170.00. Hector covers the Healthcare se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-gets-a-buy-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-gets-a-buy-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","IE00B3T34201.USD","LU2456880835.USD","LU0109394709.USD","XLV","LU0889565916.HKD","LU2462157665.USD","LABU","LU0320765992.SGD","AZN","LU2236285917.USD","BK4588","XBI","LU2417539215.USD","BK4585","BK4581","LU1829250122.USD","LU0289739699.SGD","BK4568","BK4007"],"gpt_icon":0},{"id":"2619780458","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619780458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619780458?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:01","pubTimestamp":1773648076,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dianthus Therapeutics (DNTH – Research Report) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","NERV","XBI","LU0029874061.USD","LABU","DNTH","HCSG","BK4139","LU0128526141.USD","XLV","BK4137","BK4588","BK4585"],"gpt_icon":0},{"id":"2619437021","title":"Hunan Warrant Pharmaceutical Subsidiary Passes US FDA Inspection for Peptic Ulcer Drug Raw Ingredient","url":"https://stock-news.laohu8.com/highlight/detail?id=2619437021","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619437021?lang=en_us&edition=fundamental","pubTime":"2026-03-16 15:35","pubTimestamp":1773646541,"startTime":"0","endTime":"0","summary":"Hunan Warrant Pharmaceutical  subsidiary Hunan Warrant Chiral Drugs passed the U.S. Food and Drug Administration's on-site inspection for its pantoprazole sodium active pharmaceutical ingredient.The product is used to manufacture treatments for active peptic ulcers, reflux esophagitis, and Zollinger-Ellison syndrome, according to a Saturday filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK0239","688799","LABU"],"gpt_icon":0},{"id":"2619432665","title":"J.P. Morgan Remains a Buy on Merck KGaA (0O14)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619432665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619432665?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:55","pubTimestamp":1773644119,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Richard Vosser maintained a Buy rating on Merck KGaA today and set a price target of €150.00. Vosser covers the Healthcare sect...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-merck-kgaa-0o14-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-merck-kgaa-0o14-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550494.USD","IE0009355771.USD","MRK","LU1069347547.HKD","BK4550","LU0006306889.USD","SG9999015358.SGD","LU2023250843.SGD","IE00BLSP4239.USD","LU2361044865.SGD","SG9999014575.USD","LU0980610538.SGD","LABU","LU0314104364.USD","LU0265550359.USD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","LU0528227936.USD","BK4127","LU0098860793.USD","LU1023059063.AUD","LU1699723380.USD","LU2360032135.SGD","LU1066053197.SGD","LU1941712264.USD","LU0795875169.SGD","LU1941712348.USD","LU0912757837.SGD","LU0266013472.USD","LU0965508806.USD","BK4516","LU2112291526.USD","IE00B2B36J28.USD","LU1035773651.USD","XLV","LU0985320562.USD","LU1057294990.SGD","LU1720051108.HKD","LU1093756168.USD","XBI","BK4007","LU2461242641.AUD","SG9999001176.USD","LU0868494708.USD","LU0225283273.USD","LU2361044949.HKD","LU2125154935.USD","LU0320765646.SGD","LU1116320737.USD","LU2089284900.SGD"],"gpt_icon":0},{"id":"2619346154","title":"BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100","url":"https://stock-news.laohu8.com/highlight/detail?id=2619346154","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619346154?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:33","pubTimestamp":1773642805,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BioVersys AG ( ($CH:BIOV) ). BioVersys AG has received clearance from the U.S. Food and Drug Administration to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioversys-wins-fda-go-ahead-for-global-phase-3-pneumonia-trial-of-bv100?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioversys-wins-fda-go-ahead-for-global-phase-3-pneumonia-trial-of-bv100?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"1101618720","title":"China's Basic Medical Insurance Coverage Exceeds 1.33 Billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1101618720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101618720?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:02","pubTimestamp":1773640964,"startTime":"0","endTime":"0","summary":"According to a report released on the 16th via the National Healthcare Security Administration's official WeChat account, China's basic medical insurance system saw continued growth and optimization...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1574","09939","BK4585","BK1161","BK1515","XBI","XLV","LABU","BK4581"],"gpt_icon":0},{"id":"2619431585","title":"Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619431585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619431585?lang=en_us&edition=fundamental","pubTime":"2026-03-16 13:45","pubTimestamp":1773639924,"startTime":"0","endTime":"0","summary":"Molecular Partners AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Nedelcovych from TD Cowen maint...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/undervalued-radioligand-leader-molecular-partners-differentiated-radiodarpin-platform-underpins-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/undervalued-radioligand-leader-molecular-partners-differentiated-radiodarpin-platform-underpins-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","BK4581","BK4588","LABU","XLV"],"gpt_icon":0},{"id":"2619354014","title":"COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619354014","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619354014?lang=en_us&edition=fundamental","pubTime":"2026-03-16 12:15","pubTimestamp":1773634522,"startTime":"0","endTime":"0","summary":"COMPASS Pathways, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/compass-pathways-durable-psychedelic-therapy-profile-and-clear-path-to-2027-approval-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/compass-pathways-durable-psychedelic-therapy-profile-and-clear-path-to-2027-approval-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","BK4585","XLV","BK4588","XBI"],"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":4,"totalSize":415,"code":"91000000","status":"200"}]}}